Chemours Company (The)

As of June 30, 2026, Chemours Co. carries a market capitalization of 55.66B, placing it among publicly traded companies globally. Its enterprise value stands at 115.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chemours Co.'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Chemours Co. has 150.46M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.55, and the price-to-book ratio stands at -65.01.

As of June 30, 2026, Chemours Co. trades at an EV/EBITDA multiple of 13.88 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 41.73 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 115.94B versus a market cap of 55.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chemours Co. maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -8,583.33, indicating conservative leverage, while an interest coverage ratio of 1.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -4.15, reflecting losses generated across the asset base. The company generates approximately 17.54M in revenue per employee across its workforce of 5,775.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.26 indicates how many times Chemours Co. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chemours Co. recorded 4.65B in income tax expense. The company reported a pretax loss of -681.39M and -5.31B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 2, 2026, Chemours Co.'s stock has declined approximately 4.53% over the past 52 weeks. The 50-day moving average sits at 313.53, while the 200-day moving average is 523.19.

Over the twelve months ended June 30, 2026, Chemours Co. generated 101.28B in revenue and converted that into -5.31B in net income, yielding earnings per share of -35.19. EBITDA reached 8.35B, while operating income came in at -1.45B.

As of June 30, 2026, Chemours Co. holds 11.72B in cash and equivalents against 71.98B in total debt, resulting in a net debt position of 55.93B. Total book value stands at -856.11M, with working capital of 21.54B providing operational flexibility.

Chemours Co. produced 6.94B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.13B in capital expenditures, free cash flow totaled 3.81B - equivalent to 25.28 per share.

Over the twelve months ended June 30, 2026, Chemours Co. posted a gross margin of 15.30, reflecting its pricing power and cost economics. The operating margin of -1.43 and net profit margin of -5.24 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chemours Co. paid dividends of 6.26 per share. The dividend payout ratio of -17.65 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.80, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 10.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chemours Co. shareholders.

As of June 30, 2026, Chemours Co. has an Altman Z-Score of 1.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.